Admedus : Company Secretary Appointment

Admedus Ltd

ABN 35 088 221 078

ASX ANNOUNCEMENT

REGISTERED OFFICE:

26 Harris Road Malaga Western Australia 6090

PO Box 6879

East Perth Western Australia 6892

T +61 (0)8 9266 0100

F +61 (0)8 9266 0199

Einfo.au@admedus.com www.admedus.com

Admedus Limited (ASX: AHZ) today announced the appointment of Mrs Maja McGuire to the role of Company Secretary. Mrs McGuire's appointment follows the departure of Mr Stephen Mann as noted in the Company's announcement on 26 August 2016.

Mrs McGuire has been with the Company for almost three years and will combine company secretarial duties with her role as Legal Counsel. Mrs McGuire holds a Bachelor of Laws and a Bachelor of Commerce from The University of Western Australia and has in excess of 9 years' experience in the provision of corporate and compliance advice to a number of ASX listed public companies.

Mrs McGuire commenced her career at Clayton Utz, Perth, where she gained experience in a broad range of corporate, commercial and banking & finance matters. Mrs McGuire came to Admedus in 2014 from the Canadian Bankers Association, Toronto, where she advocated on behalf of Canadian banks on issues pertaining to developments in international and domestic banking regulation related primarily to capital adequacy and funding.

Mrs McGuire will continue to oversee the legal aspects of the business and will be responsible for Admedus' statutory reporting and business administration.

Twitter: @Admedus

Facebook: www.facebook.com/pages/Admedus Website: www.admedus.com

Blog: www.admedus.com/au/category/news/

Dr Julian Chick | Chief Operating Officer | Admedus Limited Tel: +61 (0)8 9266 0100

FTI Consulting

Simon Conway / Victoria Foster Mitchell Tel: +44 (0) 20 3727 1000

admedus@fticonsulting.com

Rx Communications Group, LLC Melody A. Carey

+1 917 322 2571

mcarey@rxir.com

Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.

Further information on the company can be found on www.admedus.com